How much you love and support This beautiful President trump Family
A. Very Strong Support (100%)
B. Strong Support (75%)
C. Moderate Support (50%)
D. Limited Support (25%)
E. No Support (0%)
Be honest please
@adgirlMM Trump worries about the election being tampered with because he has had it done , that's why he's in the White House today, and he shouldn't be,he is the least person I would ever call POTUS , he's a piece of shit !!
@adgirlMM 3. Hes a giant c**t
4. Hes the most corrupt president ever
5. He endorses child murder
6. Hes a paedophile
7. Hes a rapist
8. Hes a thief
9. Hes a misogynist
10. Wants to put women back in the kitchen
11. Hes a cheat
12. Hes a disgusting excuse for a man
13. He shits himself
@adgirlMM It's simple...you are a certified criminal, sex offender & a major con-artist your entire life who pathologically lies with conviction people believed you. . Your mom was right.. you never should be in politics. You are a thousand times worse than Biden physically & mentally.
@adgirlMM Absolutely Truth and Facts! Unfortunately our country's voters are incapable of honestly recognizing DJT'S absolute Fraudulent and Incompetence! "TRUTH & FACTS!" "IGNORANCE IS NOT BLISS!" "TRUTH&FACTS!"
Dear Trump,
The reason you "won an election in a landslide and got 94% bad press" is because:
1. You didn't win in a landslide. You won the popular vote by 1.5 percent, one of the smallest presidential victory margins in history.
2. You got bad press because the majority of Americans dislike you, have never voted for you, and the press knows it.
Hope that helps.
Clinicians described the results as โone of the most amazing things Iโve ever seen.โ An experimental once-daily oral drug called daraxonrasib has produced unprecedented outcomes in advanced pancreatic cancer, reducing the risk of death by 60% compared to standard chemotherapy.
In the Phase 3 RASolute 302 trial, daraxonrasib, a RAS(ON) multi-selective inhibitor developed by Revolution Medicines, nearly doubled median overall survival from 6.6โ6.7 months with chemotherapy to 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The trial, presented as a plenary session at the 2026 ASCO Annual Meeting, triggered a rare standing ovation from oncology experts.
Unlike traditional therapies, daraxonrasib effectively targets multiple KRAS variants and even wild-type RAS, offering broad applicability to the vast majority of pancreatic cancers. The drug was also far better tolerated, with only 1.2% of patients discontinuing treatment due to side effects, compared to 11.2% in the chemotherapy arm.
This represents a major advance for a disease long considered one of the most lethal in oncology. Experts are hailing daraxonrasib as a potential paradigm shift that could transform metastatic pancreatic cancer into a more manageable condition. The FDA has already granted expanded access for eligible patients.
[OโReilly, E. M., et al. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. DOI: 10.1056/NEJMoa2605555]
Today marks 82 years since American and Allied troops stormed the beaches of Normandy on #DDay. Their courage and sacrifice helped secure freedom and changed the course of history. We honor their legacy and will never forget.